title: [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
abstract: BACKGROUND
  Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use.
  
  
  OBJECTIVE
  To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy).
  
  
  METHODS
  Patients with stage IV gastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed.
  
  
  RESULTS
  Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months.
  
  
  CONCLUSIONS
  FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity.
authors.affiliation: Departamento de Hematología-Oncología, Centro de Cáncer, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Garrido
authors.forename: Geraldine
authors.initials: G
authors.lastname: Melgoza
authors.forename: Héctor
authors.initials: H
authors.lastname: Galindo
authors.forename: Jorge
authors.initials: J
authors.lastname: Madrid
authors.forename: César
authors.initials: C
authors.lastname: Sánchez
authors.forename: Bruno
authors.initials: B
authors.lastname: Nervi
authors.forename: Manuel
authors.initials: M
authors.lastname: Alvarez
authors.forename: Eric
authors.initials: E
authors.lastname: Orellana
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D011725:Pyridines; C431073:oxiplatin; D002955:Leucovorin; D005472:Fluorouracil